Lilly’s Once-Weekly Trulicity® (dulaglutide) Label Updated to Include Data Showing Benefits for Adults with Type 2 Diabetes and Chronic Kidney Disease

Lilly’s Once-Weekly Trulicity® (dulaglutide) Label Updated to Include Data Showing Benefits for Adults with Type 2 Diabetes and Chronic Kidney Disease

July 19, 2018 Lilly’s Once-Weekly Trulicity® (dulaglutide) Label Updated to Include Data Showing Benefits for Adults with Type 2 Diabetes and Chronic Kidney Disease INDIANAPOLIS, July 19, 2018 /PRNewswire/ — The U.S. label for Eli Lilly and Company’s (NYSE: LLY) once-weekly

FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis

FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis

June 1, 2018 The approval of OLUMIANT is based on the Phase 3 clinical trial program that demonstrated efficacy for difficult to treat patients1 INDIANAPOLIS, June 1, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that

Lilly’s Taltz® (ixekizumab) Receives the First U.S. FDA Approval for Label Update to Include Data for Psoriasis Involving the Genital Area

Lilly’s Taltz® (ixekizumab) Receives the First U.S. FDA Approval for Label Update to Include Data for Psoriasis Involving the Genital Area

– The label update is effective immediately in the United States(1) – INDIANAPOLIS, May 22, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label update for Taltz® (ixekizumab) injection 80 mg/mL

Lilly Data at ASCO Illustrate Patient-Driven Advances in Cancer Care

May 16, 2018 First presentation of findings from the ramucirumab REACH-2 study – the first positive Phase 3 hepatocellular carcinoma trial in a biomarker-selected populationResearch across the MONARCH clinical development program reinforcing the benefit of abemaciclib in advanced breast cancer

Lilly’s Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache

INDIANAPOLIS, May 15, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that galcanezumab met its primary endpoint in a Phase 3 study of patients with episodic cluster headache, demonstrating statistically significant differences in the reduction of weekly cluster headache attacks compared

Lilly to Acquire AurKa Pharma

Acquisition Expands Lilly Oncology Pipeline with Early-Phase Asset Being Studied in Multiple Tumor Types INDIANAPOLIS, May 14, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced an agreement to acquire AurKa Pharma, Inc., a company established by TVM Capital Life Science to develop

Lilly Announces Agreement To Acquire ARMO BioSciences

$1.6 billion transaction will bolster Lilly’s clinical portfolio with ARMO’s lead immuno-oncology asset, pegilodecakin, which is being studied in multiple tumor types INDIANAPOLIS and REDWOOD CITY, Calif., May 10, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and ARMO BioSciences, Inc. (NASDAQ: ARMO) today announced a definitive

Lilly and Local Partners Launch Diabetes Prevention and Management Pilot in Three Underserved Neighborhoods in Indianapolis

New $7 Million Intervention Brings Global Approach to U.S., Leveraging the Expertise of Fairbanks School of Public Health and Other Local Partners INDIANAPOLIS, May 1, 2018 – Eli Lilly and Company (NYSE: LLY) and Indiana University’s Richard M. Fairbanks School

Lilly to Participate in Bank of America Merrill Lynch Health Care Conference

INDIANAPOLIS, April 27, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Merrill Lynch 2018 Health Care Conference on Wednesday, May 16, 2018. Christi Shaw, senior vice president and president of Lilly Bio-Medicines will participate in a fireside chat at 8:00 a.m. PDT(11:00 a.m.

Lilly and China’s NCCD announce collaboration to advance scientific understanding and care for people living with diabetes and cardiovascular disease

– Collaboration between China’s National Center for Cardiovascular Diseases and Lilly aims to improve care for people living with Type 2 diabetes in China– The Lilly and NCCD collaboration will address four strategic areas to advance scientific understanding and medical

AAN 2018: Lilly’s Galcanezumab Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed to Respond to Multiple Preventive Therapies

INDIANAPOLIS, April 24, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today results from a post-hoc subgroup analysis which demonstrated efficacy of galcanezumab in patients with episodic and chronic migraine who previously failed to respond to two or more preventive therapies. Detailed